HRP20171264T1 - Konjugati protutijela anti-her2-pirolobenzodiazepina - Google Patents
Konjugati protutijela anti-her2-pirolobenzodiazepina Download PDFInfo
- Publication number
- HRP20171264T1 HRP20171264T1 HRP20171264TT HRP20171264T HRP20171264T1 HR P20171264 T1 HRP20171264 T1 HR P20171264T1 HR P20171264T T HRP20171264T T HR P20171264TT HR P20171264 T HRP20171264 T HR P20171264T HR P20171264 T1 HRP20171264 T1 HR P20171264T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- conjugate according
- antibody
- seq
- domain
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229940125644 antibody drug Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Claims (14)
1. Konjugat, naznačen time, da ima sljedeće formule
ConjA:
[image]
ConjB:
[image]
ConjC:
[image]
ConjD:
[image]
ili
ConjE:
[image]
gdje Ab predstavlja protutijelo koje se veže na HER2, pri čemu protutijelo obuhvaća VH-domenu koja ima sekvencu u skladu sa
SEQ ID NO:1; i
pri čemu popunjenje supstancom (p) od lijekova (D) spram protutijela (Ab), iznosi cijeli broj od 1 do oko 8.
2. Konjugat prema zahtjevu 1, naznačen time, da protutijelo obuhvaća VH-domenu koja je sparena s VL-domenom, pri čemu
VH-domena i VL-domena imaju sekvence od SEQ ID NO:1 u paru sa
SEQ ID NO:2.
3. Konjugat prema zahtjevu 1 ili zahtjevu 2, naznačen time, da protutijelo je nedirnuto protutijelo.
4. Konjugat prema zahtjevu 3, naznačen time, da protutijelo obuhvaća jaki lanac koji ima sekvencu od SEQ ID NO:3 u paru sa
slabim lancem koji ima sekvencu od SEQ ID NO:4.
5. Konjugat prema zahtjevu 4, naznačen time, da protutijelo obuhvaća dva jaka lanca koji imaju sekvencu od SEQ ID NO:3, od kojih je svaki sparen sa slabim lancem koji ima sekvencu od SEQ ID NO:4.
6. Konjugat prema bilo kojem od zahtjeva 1 do 5, naznačen time, da je protutijelo humanizirano, deimunizirano ili je površinski preformirano.
7. Konjugat prema zahtjevu 1, naznačen time, da p je 1, 2, 3 ili 4.
8. Konjugat prema zahtjevu 1, naznačen time, da obuhvaća konjugirane spojeve protutijelo-lijek, pri čemu prosječno popunjenje supstancom po protutijelu, u mješavini konjugiranih spojeva protutijelo-lijek, iznosi od oko 2 do oko 5.
9. Konjugat prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se upotrebljava u liječenju.
10. Konjugat prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se upotrebljava u liječenju proliferativne bolesti kod pojedinca.
11. Konjugat prema zahtjevu 10, naznačen time, da bolest je rak.
12. Konjugat prema zahtjevu 11, naznačen time, da je rak odabran iz skupine koja se sastoji od sljedećih: rak dojke, rak želudca, rak mjehura, rak gušterače, kolorektalni rak, rak cerviksa, rak jajnika, rak prostate, rak ne-malih stanica pluća, endometrijski rak, rak glave i vrata te karcinom žlijezde slinovnice.
13. Farmaceutski sastav, naznačen time, da obuhvaća konjugat prema bilo kojem od zahtjeva 1 do 8, te farmaceutski prihvatljiv razrjeđivač, nosač ili pomoćno sredstvo.
14. Farmaceutski sastav prema zahtjevu 13, naznačen time, da dodatno obuhvaća terapeutski učinkovitu količinu kemoterapeutskog sredstva.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261712924P | 2012-10-12 | 2012-10-12 | |
US201261712928P | 2012-10-12 | 2012-10-12 | |
US201361784270P | 2013-03-14 | 2013-03-14 | |
US201361784249P | 2013-03-14 | 2013-03-14 | |
US201361784233P | 2013-03-14 | 2013-03-14 | |
PCT/EP2013/071343 WO2014057115A1 (en) | 2012-10-12 | 2013-10-11 | Pyrrolobenzodiazepine-anti-her2 antibody conjugates |
EP13788691.7A EP2906252B1 (en) | 2012-10-12 | 2013-10-11 | Pyrrolobenzodiazepine-anti-her2 antibody conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171264T1 true HRP20171264T1 (hr) | 2017-10-20 |
Family
ID=49552324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171264TT HRP20171264T1 (hr) | 2012-10-12 | 2017-08-17 | Konjugati protutijela anti-her2-pirolobenzodiazepina |
Country Status (21)
Country | Link |
---|---|
US (1) | US20150273077A1 (hr) |
EP (1) | EP2906252B1 (hr) |
JP (1) | JP2016502504A (hr) |
KR (1) | KR20150083856A (hr) |
CN (1) | CN104955485B (hr) |
AU (1) | AU2013328621B2 (hr) |
BR (1) | BR112015008177A2 (hr) |
CA (1) | CA2887896A1 (hr) |
CY (1) | CY1119287T1 (hr) |
DK (1) | DK2906252T3 (hr) |
ES (1) | ES2640449T3 (hr) |
HR (1) | HRP20171264T1 (hr) |
HU (1) | HUE034505T2 (hr) |
LT (1) | LT2906252T (hr) |
MX (1) | MX2015004423A (hr) |
PL (1) | PL2906252T3 (hr) |
PT (1) | PT2906252T (hr) |
RS (1) | RS56222B1 (hr) |
SI (1) | SI2906252T1 (hr) |
WO (1) | WO2014057115A1 (hr) |
ZA (1) | ZA201502267B (hr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
EP2558475A1 (en) | 2010-04-15 | 2013-02-20 | Spirogen Sàrl | Pyrrolobenzodiazepines used to treat proliferative diseases |
WO2011130613A1 (en) | 2010-04-15 | 2011-10-20 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazapine conjugates |
EP2751120B1 (en) | 2011-09-20 | 2018-08-22 | MedImmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
EP3309162A1 (en) | 2011-10-14 | 2018-04-18 | Seattle Genetics, Inc. | Targeted conjugates of pyrrolobenzodiazepines |
US9388187B2 (en) | 2011-10-14 | 2016-07-12 | Medimmune Limited | Pyrrolobenzodiazepines |
BR112014008888A2 (pt) | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
EP2755642B1 (en) | 2011-10-14 | 2018-07-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
SI2766048T1 (sl) | 2012-10-12 | 2015-03-31 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
CA2885315C (en) | 2012-10-12 | 2020-06-23 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
ES2658888T5 (es) | 2012-12-21 | 2021-10-19 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
BR112015021965B1 (pt) | 2013-03-13 | 2022-05-03 | Medimmune Limited | Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos |
CA2901941C (en) | 2013-03-13 | 2020-04-07 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2016037644A1 (en) * | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
PL3191135T3 (pl) | 2014-09-12 | 2021-01-25 | Genentech, Inc. | Przeciwciała i immunokoniugaty anty-HER2 |
MX2017003472A (es) * | 2014-09-17 | 2017-10-31 | Genentech Inc | Inmunoconjugados que comprenden anticuerpos anti-her2. |
BR112017011111A2 (pt) | 2014-11-25 | 2017-12-26 | Adc Therapeutics Sa | conjugados de pirrolobenzodiazepina-anticorpo |
US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
GB201506394D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506389D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
TWI726942B (zh) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性her2抗體藥物共軛體 |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN106248971B (zh) * | 2016-08-19 | 2017-10-03 | 合肥瀚科迈博生物技术有限公司 | 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途 |
GB201617466D0 (en) * | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB201619490D0 (en) * | 2016-11-17 | 2017-01-04 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
PL3579883T3 (pl) | 2017-02-08 | 2022-01-24 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało |
BR112019016373B1 (pt) | 2017-02-08 | 2022-01-25 | Medimmune Limited | Conjugado anticorpo-fármaco que se liga ao axl, composição e composição farmacêutica que compreende o mesmo e uso terapêutico do dito conjugado |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
PT3612537T (pt) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
JP7408396B2 (ja) | 2017-04-20 | 2024-01-05 | アーデーセー セラピューティクス ソシエテ アノニム | 併用療法 |
MX2019012465A (es) | 2017-04-20 | 2020-07-27 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25. |
EP3638372A1 (en) | 2017-06-14 | 2020-04-22 | ADC Therapeutics SA | Dosage regimes for the administration of an anti-cd25 adc |
EA039276B1 (ru) * | 2017-08-18 | 2021-12-27 | Медимьюн Лимитед | Пирролобензодиазепиновые конъюгаты |
IL301638B1 (en) | 2017-09-29 | 2024-05-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a pyrrolobenzodiazepine derivative |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
US11141490B2 (en) * | 2018-07-13 | 2021-10-12 | Research Foundation Of The City University Of New York | Antibody-drug conjugates based on gold compounds |
AU2020246448A1 (en) * | 2019-03-25 | 2021-10-14 | Daiichi Sankyo Company, Limited | Anti-HER2 antibody-pyrrolobenzodiazepine derivative conjugate |
GB201908128D0 (en) * | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
MX2022001812A (es) | 2019-08-12 | 2022-03-11 | Regeneron Pharma | Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos. |
GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1720881T3 (pl) * | 2004-03-01 | 2013-05-31 | Medimmune Ltd | Pochodne 11-hydroksy-5h-pirolo[2,1-c][1,4]benzodiazepin-5-onu jako kluczowe związki pośrednie do otrzymywania C2 podstawionych pirolobenzodiazepin |
GB0508084D0 (en) * | 2005-04-21 | 2005-06-01 | Spirogen Ltd | Pyrrolobenzodiazepines |
US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
GB0819095D0 (en) * | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
AU2010265934B2 (en) * | 2009-06-26 | 2015-04-23 | Five Prime Therapeutics, Inc. | Therapeutic antibody target validation and screening in vivo |
EP2558475A1 (en) * | 2010-04-15 | 2013-02-20 | Spirogen Sàrl | Pyrrolobenzodiazepines used to treat proliferative diseases |
MA34277B1 (fr) * | 2010-04-15 | 2013-06-01 | Spirogen Developments Sarl | Pyrrolobenzodiazépines et conjugués de celles-ci |
WO2011130613A1 (en) * | 2010-04-15 | 2011-10-20 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazapine conjugates |
US9586996B2 (en) * | 2010-04-30 | 2017-03-07 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
MX364707B (es) * | 2011-05-08 | 2019-05-06 | Legochem Biosciences Inc | Conjugados de proteina-agente activo y método para su preparación. |
EA026827B1 (ru) * | 2011-10-14 | 2017-05-31 | Медимьюн Лимитед | Пирролбензодиазепины и их конъюгаты |
WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
-
2013
- 2013-10-11 SI SI201330762T patent/SI2906252T1/sl unknown
- 2013-10-11 PL PL13788691T patent/PL2906252T3/pl unknown
- 2013-10-11 BR BR112015008177A patent/BR112015008177A2/pt not_active IP Right Cessation
- 2013-10-11 CA CA2887896A patent/CA2887896A1/en not_active Abandoned
- 2013-10-11 RS RS20170839A patent/RS56222B1/sr unknown
- 2013-10-11 EP EP13788691.7A patent/EP2906252B1/en active Active
- 2013-10-11 US US14/434,810 patent/US20150273077A1/en not_active Abandoned
- 2013-10-11 ES ES13788691.7T patent/ES2640449T3/es active Active
- 2013-10-11 PT PT137886917T patent/PT2906252T/pt unknown
- 2013-10-11 KR KR1020157012365A patent/KR20150083856A/ko not_active Application Discontinuation
- 2013-10-11 AU AU2013328621A patent/AU2013328621B2/en not_active Ceased
- 2013-10-11 LT LTEP13788691.7T patent/LT2906252T/lt unknown
- 2013-10-11 HU HUE13788691A patent/HUE034505T2/en unknown
- 2013-10-11 DK DK13788691.7T patent/DK2906252T3/en active
- 2013-10-11 CN CN201380065413.1A patent/CN104955485B/zh not_active Expired - Fee Related
- 2013-10-11 JP JP2015536163A patent/JP2016502504A/ja active Pending
- 2013-10-11 WO PCT/EP2013/071343 patent/WO2014057115A1/en active Application Filing
- 2013-10-11 MX MX2015004423A patent/MX2015004423A/es unknown
-
2015
- 2015-04-07 ZA ZA2015/02267A patent/ZA201502267B/en unknown
-
2017
- 2017-08-17 HR HRP20171264TT patent/HRP20171264T1/hr unknown
- 2017-09-05 CY CY20171100933T patent/CY1119287T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2906252B1 (en) | 2017-06-14 |
CN104955485B (zh) | 2018-01-30 |
SI2906252T1 (sl) | 2017-10-30 |
CY1119287T1 (el) | 2018-02-14 |
KR20150083856A (ko) | 2015-07-20 |
LT2906252T (lt) | 2017-09-11 |
ES2640449T3 (es) | 2017-11-03 |
WO2014057115A1 (en) | 2014-04-17 |
BR112015008177A2 (pt) | 2017-09-19 |
AU2013328621A1 (en) | 2015-04-23 |
RS56222B1 (sr) | 2017-11-30 |
MX2015004423A (es) | 2015-10-29 |
ZA201502267B (en) | 2017-09-27 |
CA2887896A1 (en) | 2014-04-17 |
PL2906252T3 (pl) | 2017-11-30 |
JP2016502504A (ja) | 2016-01-28 |
EP2906252A1 (en) | 2015-08-19 |
HUE034505T2 (en) | 2018-02-28 |
CN104955485A (zh) | 2015-09-30 |
DK2906252T3 (en) | 2017-09-11 |
AU2013328621B2 (en) | 2016-12-01 |
US20150273077A1 (en) | 2015-10-01 |
PT2906252T (pt) | 2017-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171264T1 (hr) | Konjugati protutijela anti-her2-pirolobenzodiazepina | |
HRP20171916T1 (hr) | Konjugati protutijelo anti-cd22 - pirolobenzodiazepin | |
HRP20181646T2 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
HRP20190672T1 (hr) | Konjugirane formulacije anti-egfr protutijelo-lijek | |
JP2016515511A5 (hr) | ||
HRP20180945T1 (hr) | Konjugati protutijelo-pirolobenzodiazepin | |
HRP20191335T1 (hr) | Anti-egfrviii antitijela i njihove primjene | |
HRP20210593T1 (hr) | Anti-her3 antitijelo-lijek konjugat | |
HRP20211125T1 (hr) | Konjugati protutijelo-lijek koji se temelje na eribulinu i postupci uporabe | |
HRP20211129T1 (hr) | Nukleinske kiseline koje kodiraju humana antitijela na sialyl-lewis a | |
HRP20192285T1 (hr) | Anti-ox40 protutijela i postupci uporabe | |
RU2014138474A (ru) | Новые модуляторы и способы применения | |
HRP20211710T1 (hr) | Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat | |
HRP20201186T1 (hr) | Konjugati protutijela protiv cmet s lijekom i postupci njihove upotrebe | |
HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
HRP20231609T1 (hr) | Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2 | |
HRP20171789T1 (hr) | Konjugati humanog protutijela s lijekom protiv tkivnog faktora | |
HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
PE20181302A1 (es) | Nuevos anticuerpos anti-claudina y sus metodos de uso | |
HRP20201091T1 (hr) | Protutijela anti-axl | |
HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
JP2016502504A5 (hr) | ||
HRP20221041T1 (hr) | Anti-pd-1 antitijela i sastavi | |
RU2018119683A (ru) | Сайт-специфические конъюгаты антитела к her2 и лекарственного средства | |
JP2019506398A5 (hr) |